Pre- treatment protoporphyrin IX concentration in actinic keratosis lesions predicts response to aminolevulinic-acid based photodynamic therapy

Document Type

Conference Proceeding

Publication Date

9-1-2015

Publication Title

SPIE/NIH

Department

Thayer School of Engineering

Abstract

Although Aminolevulinic Acid (ALA)-induced protoporphyrin IX (PpIX) photodynamic therapy (PDT) is an effective FDA-approved therapy for actinic keratosis (AK), a substantial fraction of patients (up to 25%) do not respond to treatment. This study examined the feasibility of using pre-treatment measurements of PpIX concentration in AK lesions to predict response of ALA-PpIX PDT.

DOI

10.1016/j.pdpdt.2015.10.006

Share

COinS